Imatinib Sandoz Ltd

Imatinib mesylate, the active ingredient in Imatinib Sandoz Ltd, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for certain blood cancers and gastrointestinal stromal tumors in adult patients. GNH USA supplies Imatinib Sandoz Ltd as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib Sandoz Ltd targets abnormal tyrosine‑kinase signaling in specific malignancies. - Chronic myeloid leukemia: suppresses BCR‑ABL driven proliferation, achieving hematologic and cytogenetic remission. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: blocks BCR‑ABL activity to improve remission rates. - Gastrointestinal stromal tumor: inhibits c‑KIT and PDGFR signaling, reducing tumor growth and recurrence.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the lower extremities. - Muscle cramps: intermittent painful contractions. - Fatigue: generalized lack of energy. - Diarrhea: loose stools occurring intermittently. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Neutropenia: marked reduction in neutrophil count, increasing infection risk. - Hepatotoxicity: elevated liver enzymes or clinical hepatitis. - Cardiac failure: signs of reduced cardiac output, such as dyspnea or edema. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Pulmonary hypertension: unexplained shortness of breath and elevated pulmonary pressures.

Patients should be monitored for safety and efficacy throughout therapy. - Monitor blood counts: perform regular CBC to detect cytopenias. - Assess liver function: check transaminases and bilirubin periodically. - Evaluate cardiac status: baseline and follow‑up ECG or echocardiogram for patients with cardiac history. - Avoid use in patients with known hypersensitivity to imatinib or its excipients. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with other medicines, altering its concentration or effect.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib plasma levels and toxicity. - Concomitant warfarin: enhanced anticoagulant effect, raising bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower imatinib exposure, reducing efficacy. - Antacids containing aluminum or magnesium: can impair oral absorption of imatinib. - Live vaccines: potential reduced immunogenicity, consider timing relative to therapy.